We are pleased to invite applications for PhD studentships from candidates wishing to carry out research under one of our three priority themes: neuro-oncology, acquired brain and spinal cord injury, and headache and facial pain.
We would like to receive applications from prospective students - both clinical and non-clinical - planning to embark upon a PhD in Autumn 2022, focused on one of the three priority areas outlined below.
The application deadline is midday on Monday 15th November 2021.
We want to fund hypothesis-driven pre-clinical or clinical research that addresses large unmet need, and demonstrates a clear pathway to clinical impact in one of the following three areas:
The maximum award is £120,000 - including student stipend, fees at the Home level, direct research costs, and conference/training costs. For clinical candidates, stipend can be used to support a salary at the appropriate clinical level, however the balance of funds will need to be obtained from other sources.
Applications must be submitted via our research portal. Please read the guidance notes in full and familiarise yourself with the system so that you know exactly what is required and are able to submit all components by the 15th November deadline.
We expect the research proposal to be developed by the candidate, in collaboration with their proposed supervisor.
Applications will be reviewed and short-listed by the members of our Scientific Advisory Panel. They will consider the applicant's academic track record, previous research experience, and future academic potential as well as the merits of the research proposal.
Short-listed research proposals will be subject to external peer review - and will be judged on scientific merit, originality, and the potential for impact.
Short-listed candidates will be invited for interview in February 2022 with our Scientific Advisory Panel. Interviews are expected to take place in London but this will be kept under review in light of developments related to Covid-19.
Further details can be found in the guidance notes below: